GlaxoSmithKline Pharmaceuticals logo

GlaxoSmithKline Pharmaceuticals financials and balance sheet

NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap

Formerly Glaxo (India)
Last close ₹2,404.70down ₹29.00 (1.19%)BSE ₹2,404.80

Share price at the NSE close on 23 Oct 2026. Previous close ₹2,433.70.

52-week range of traded prices to 23 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
Market cap
₹40,737 Cr221st largest listed
P/E
38.1
P/B
18.0
Dividend yield
2.37%
ROE
50.6%
ROCE
56.3%
Debt to equity
0.00
Volume, NSE
56,17458.6% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.GlaxoSmithKline Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 2.6% of operating profit in the first full year.

The years either side of a change of basis do not compare. From the year to Mar 2022, the company's revenue for that year, ₹3,278 Cr, differs from its quarters added, ₹3,425 Cr; the company reports a discontinued business.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue3,822
  2. Materials and goods−1,351
  3. Employee costs−607
  4. Other expenses−554
  5. Operating profit1,309
  6. Depreciation−66
  7. Other income+145
  8. One-off items+21
  9. Finance costs−2.7
  10. Profit before tax1,406
  11. Tax−370
  12. Net profit1,036

What the company owns

  • Cash and bank₹1,391 Cr
  • Current investments₹1,391 Cr
  • Plant, investments and other assets₹811 Cr
  • Inventory₹458 Cr
  • Receivables₹273 Cr

What pays for it: net worth and liabilities

  • Net worth₹2,285 Cr
  • Other liabilities₹1,469 Cr
  • Owed to suppliers₹570 Cr

Profit and loss

Consolidated, ₹ crore, years to March.GlaxoSmithKline Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 20 MayMar 2020Filed 19 MayMar 2021Filed 19 MayMar 2022Filed 17 MayMar 2023Filed 18 MayMar 2024Filed 18 MayMar 2025Filed 12 JunMar 2026Filed 13 May
Revenue from operations3,0002,8963,1283,2243,1993,2783,2523,4543,7493,822
–2,3902,5272,5672,5042,5162,4472,5452,5722,512
Materials and goods bought1,3981,2411,3581,3081,3131,3561,2851,3351,3911,351
Employee costs––537629615610595624580607
Other expenses––632631576550568586601554
Operating profit before depreciation–5066016576957628049091,1771,309
Operating margin–17.5%19.2%20.4%21.7%23.2%24.7%26.3%31.4%34.3%
Materials, % of revenue––43.4%40.6%41.0%41.4%39.5%38.6%37.1%35.4%
Employee costs, % of revenue––17.2%19.5%19.2%18.6%18.3%18.1%15.5%15.9%
Other expenses, % of revenue––20.2%19.6%18.0%16.8%17.5%17.0%16.0%14.5%
Depreciation and amortisation26384983796866706766
Operating profit after depreciation–4685525756166947398391,1111,243
Other income73551027911176101123146145
Finance costs–016422213
Profit before one-off items and tax4655226546477237678379601,2551,385
One-off items461829−341−17312−1−144521
Profit before tax5115406833065517798368161,2601,406
174189237213192398229226332370
Profit from discontinued businesses–––––1,3143–––
Net profit337351445933581,6956115909281,036
Other comprehensive income––−5−4−2−2−6−4−3−8
Total comprehensive income––440893561,6936055869251,028
Net margin11.2%12.1%14.2%2.9%11.2%–18.8%17.1%24.7%27.1%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2017: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given. Net margin is left blank for the year to Mar 2022: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 20 MayMar 2020Filed 19 MayMar 2021Filed 19 MayMar 2022Filed 17 MayMar 2023Filed 18 MayMar 2024Filed 18 MayMar 2025Filed 12 JunMar 2026Filed 13 May
2,1401,8211,4992,6631,7411,7781,9512,285
2,1401,8211,4992,6631,7411,7781,9512,267
Share capital169169169169169169169169
Reserves1,9701,6511,3302,4941,5721,6081,7822,098
Belonging to outside owners of subsidiaries0–0–00017
Borrowings00000000
1,4541,0241,3321,6981,3261,5251,9051,779
317291282272259254252260
3,9113,1363,1134,6333,3273,5574,1084,324
1,9021,051564728618545502539
2,0062,0852,3693,9062,7083,0123,6063,785
Net debt−1,171−1,083−1,158−2,850−1,674−1,876−2,522−2,782
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 19 MayMar 2022Filed 17 MayMar 2023Filed 18 MayMar 2024Filed 18 MayMar 2025Filed 12 JunMar 2026Filed 13 May
5788114845821,290903
7439597569761,3721,222
46120−4661185−98
Receivables−1001020−30−7318
Inventories−471275−654324
Payables107102−15319077−139
Other working capital85−513−34137−1
Tax paid−147−121−265−254−82−319
Capital spending443544312355
Free cash flow5347764405511,267848
419−4068089−46397
−696−524−1,543−561−769−737
Dividends paid6785071,526542749714
Shares bought back000000
Shares issued000000
Net change in cash300−119−25129475563
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020. Interest paid is left blank for the year to Mar 2023: the line is filed below nought and is smaller than the rounding of its section's total, so the statement does not show which way it moved cash.

Per share

Consolidated, ₹ per share, years to March.GlaxoSmithKline Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 20 MayMar 2020Filed 19 MayMar 2021Filed 19 MayMar 2022Filed 17 MayMar 2023Filed 18 MayMar 2024Filed 18 MayMar 2025Filed 12 JunMar 2026Filed 13 May
₹19.90₹20.71₹26.29₹5.50₹21.14₹100.04₹36.05₹34.83₹54.52–
As stated that year₹39.80₹41.41₹26.29₹5.50₹21.14₹100.04₹36.05₹34.83₹54.52–
₹19.90₹20.71₹26.29₹5.50₹21.14₹100.04₹36.05₹34.83––
₹15.00₹17.50₹20.00₹40.00₹30.00₹90.00₹32.00₹32.00₹54.00₹57.00
Book value per share––₹126.31₹107.47₹88.49₹157.19₹102.79₹104.93₹115.18₹133.85
Dividend payout75.4%84.5%76.1%727.1%141.9%90.0%88.8%91.9%98.6%93.2%
Shareholder yield––––2.8%1.8%6.8%1.6%1.5%1.8%
Market cap at the year end (₹ crore)23,24717,68421,98021,30124,40728,23822,44232,97748,79538,675
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from. As stated that year and earnings per share are left blank for the year to Mar 2026: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.
RatioMar 2017Mar 2018Mar 2019Filed 20 MayMar 2020Filed 19 MayMar 2021Filed 19 MayMar 2022Filed 17 MayMar 2023Filed 18 MayMar 2024Filed 18 MayMar 2025Filed 12 JunMar 2026Filed 13 May
Revenue growth8.4%−3.5%8.0%3.1%−0.8%–−0.8%6.2%8.6%1.9%
Operating profit growth––18.8%9.4%5.8%–5.6%13.0%29.6%11.2%
Net profit growth−10.6%4.1%27.0%−79.1%284.3%–−64.0%−3.4%57.2%11.7%
Earnings per share growth–4.0%27.0%−79.1%284.2%–−64.0%−3.4%56.5%–
––20.8%4.7%21.6%81.4%27.7%33.5%49.8%49.1%
–––−16.1 pts16.9 pts59.9 pts−53.7 pts5.8 pts16.2 pts−0.6 pts
From the net margin–––−16.6 pts13.5 pts––−2.5 pts15.0 pts4.8 pts
From asset turnover–––0.6 pts2.2 pts––5.8 pts−1.2 pts−4.0 pts
From borrowing–––−0.1 pts1.2 pts––2.5 pts2.4 pts−1.4 pts
Return on capital employed––25.8%31.6%41.1%26.0%42.4%47.2%56.9%54.4%
Cash conversion––––161.4%47.8%79.3%98.7%139.1%87.2%
Interest cover–2,462.21,004.090.7174.5346.8408.0466.1847.8455.2
Debt to equity––0.000.000.000.000.000.000.000.00
Receivable days––1411252322232826
Inventory days––131135152144131144126124
Payable days––109100129154122171186154
Cash conversion cycle, days––3646471331−4−31−4
Working capital days––−72−3−14−72−33−41−80−74
Asset turnover––0.800.921.020.850.821.000.980.91
Assets per rupee of net worth––1.831.781.881.861.811.962.062.00
Sales per rupee of plant––8.584.569.3811.1111.0311.6413.9113.97
Capital spending to depreciation––––0.560.510.670.450.340.83
Plant being built, % of plant in use––275.1%17.0%3.9%10.3%6.9%4.7%5.3%12.0%
From the net margin, from asset turnover and from borrowing are left blank for the years to Mar 2022 and Mar 2023: the profit of this year or the year before includes a business the company has discontinued while its revenue does not, so the change in return on equity is not split into margin, turnover and borrowing. Revenue growth and operating profit growth are left blank for the year to Mar 2022: between the two periods the company restated its earlier figures and the company began reporting a business as discontinued, so the two are on different bases and the change is not worked out. Net profit growth and earnings per share growth are left blank for the year to Mar 2022: between the two periods the company began reporting a business as discontinued, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
24.6%
Cash from operations against operating profit
69.0%
Measure10 years5 years3 years
Revenue growth, yearly rate3.3%3.6%5.5%
Profit growth, yearly rate10.6%23.7%19.3%
Return on equity, average–48.3%44.1%
Return on capital employed, average–45.4%52.8%
Operating margin, average24.3%28.0%30.7%
Net margin, average15.5%21.9%23.0%
Asset turnover, average–0.910.96
Cash conversion cycle, days, average–1−13
Interest cover, average695.0504.8589.7
Debt to equity, average–0.000.00

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations4,0702,775903
Cash from investing762360397
Cash from financing−4,136−2,068−737
Capital spending18811055
Dividends paid4,0372,005714
Shares bought back000
Shares issued for cash000
Borrowings raised000
Borrowings repaid000

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––664675
Altman Z-scorePublished threshold 1.81––9.7012.2211.6811.1911.4613.9916.6014.57
Beneish M-scorePublished threshold −1.78––––−1.80−3.01−2.39−2.48−2.72−2.33
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−20.4333.29−17.12−0.02−8.26−6.27
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.700.651.111.09
Receivables growth less revenue growthOur threshold 0 percentage points–––−20.25116.82−7.28−5.469.2223.19−8.58
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––2.9812.81−5.51−8.7210.28−12.47−2.16
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––5.920.95−4.072.030.20−2.10−0.99
Assets under construction, years of additionsOur threshold 2 years of additions–––0.28–1.370.310.190.360.47
Effective tax ratePublished threshold 17.16 per cent34.1135.0534.7669.5234.9451.1227.3527.7226.3826.32
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––35.65−4.30−3.4319.893.65
A threshold marked as ours has no published figure; it is the line we read the check against.